

**Detection of Epstein - Barr virus Type1 and Type2 in Subtypes of Non- Hodgkin Lymphoma in Kerbela Province by Using Polymerase Chain Reaction.**

**التحري عن فيروس الابسن بار النمط الاول النمط الثاني في الانواع الفرعية  
للاورام اللمفاوية اللاهودجكن في مدينة كربلاء بواسطة تفاعل الكوثررة .**

**Hussein Abd Ali Mohamed Sadeq Al Her**

**B. Sc., microbiology, College of Science,**

**Al-Mustansiriya University**

**Prof. Dr. Mohanad Mohsen Ahmed**

**University of kerbala, College of Medicine, Department of Medical  
Microbiology**

**Consultive . Dr. Haider Jebur Kehiosh**

**Al-Hussein Teaching Hospital, Laboratory of Histopathology**

**Abstract**

Epstein-Barr virus (EBV) is a ubiquitous virus associated with lymphomas. However, in Kerbala as other parts of Iraq, EBV detection is not a part of the workup for lymphoma diagnosis.

. Archival formalin-fixed paraffin- embedded blocks from 44 patients with mean age  $45.9 \pm 22.8$  (range from 4 to 86 years) diagnosed as Non Hodgkin lymphoma during the period from 2010 to 2018 in Kerbala city included in this study. Histological diagnosis was reviewed. Around 25mg of archival tissue were used to extract DNA. DNA extracts were used Polymerase Chain Reaction (PCR) targeting the EBNA3C region of the viral genome. This PCR system offered detection and typing of the EBV. T-test and chi-square were used to evaluate the association between age with the subtype of Non Hodgkin lymphoma, gender and EBV state.

The majority of the Non Hodgkin lymphomas (NHL) belonged diffuse large B cell (DLBC) [n=28, 63.6%], T-cell rich Diffuse large B-cell [n=9, 20.5%], high grade B cell Burkitt- like (BL) [n=3, 6.8%], small B lymphocytic [n=2, 4.5%], high grade B cell (CD20-ve, CD30-ve) [n=1, 2.3%] and peripheral T-cell [n=1, 2.3%]. The other subtypes of NHL were not reported in this study. Male and female were equal affected with NHL (22 for each) and the peak age range of NHL over 60 years. EBV was detected in 21 (47%) out of all cases. EBV type 1 was more common to EBV2 in all subtype of NHL. To our knowledge, this is the first- time such data has been generated in Iraq. In this study present evidence that Non- Hodgkin lymphoma cases in Kerbela are associated with EBV1 and EBV2 types. There is a difference in the distribution of the EBV types according to the subtypes of lymphoma. The aim of this study: to detect types of EBV in the subtype of Non- Hodgkin lymphoma (NHL) among patients from Kerbala province, Iraq

**Keywords:** Epstein Barr virus type1 and type 2, Non Hodgkin lymphoma subtype, molecular detection.

### المستخلص

يعتبر فيروس ابسن بار فيروس شائع الانتشار ويكون عادة مرتبط بالأورام اللمفاوية. ومع ذلك ، في كربلاء وفي مدن العراق الأخرى ، لا يعتبر كشف الفايروس جزءاً من عملية تشخيص الإصابة بالورم اللمفاوي. تهدف هذه الدراسة التحري عن مدى انتشار أنماط الفايروس في الأنواع الفرعية من الأورام اللمفاوية اللاهودجكين بين المرضى من محافظة كربلاء ، العراق. استخدمت الشرائح النسيجية المثبتة بالفومالين والمغمورة بالشمع لـ 44 مريض بمتوسط العمر  $45.9 \pm 22.8$  (تتراوح اعمارهم من 4 إلى 86 سنة) المشخصين بورم الغدد اللمفاوية اللاهودجكين خلال الفترة من 2010 إلى 2018 في مدينة كربلاء تم دراستها. تم مراجعة التشخيص النسيجي من قبل مختص الأنسجة . استخدم حوالي 25 ملغم من المقاطع النسيجية المخزونه لاستخلاص الحمض النووي. تم استخدام مستخلصات الحمض النووي في تفاعلات الكوثرية باستهداف منطقة الجين *EBNA3C* في الجينوم الفيروسي. استخدم التفاعل لتشخيص الفايروس وتميز أنواع فايروس ابسن بار. تم استخدام اختبار تي و مربع كاي لتقييم الارتباط بين العمر بالانواع الفرعية من سرطان الغدد اللمفاوية اللاهودجكين والجنس ومقارنتها مع نتائج تشخيص الفايروس. أظهرت النتائج ان غالبية الأورام اللمفاوية اللاهودجكين بانها تنتمي إلى النوع الفرعي *DLBC* حيث كانت 28 (63.6%) حالة ثم النوع الفرعي المختلط صغير وكبير *T-cell rich Diffuse large B-cell* في 9 (20.5%) حالة ، و البركت لمفوما *BL 3* (6.8%) واحد حالة لكل من *HGBC* و *PTC*. ولم تسجل حالات من الأنواع الفرعية الأخرى من الأورام اللمفاوية الهوجكن في هذه الدراسة. الذكور ، الإناث نفس عدد الاصابات بالأورام اللمفاوية اللاهودجكين (22). كانت الفئة العمرية أكثر من 60 عاما الأكثر إصابة بالأورام اللمفاوية اللاهودجكين . تم الكشف عن الفايروس في 21 (47%) حالة من جميع الحالات. كان *EBV1* أكثر شيوعاً في جميع الأنواع الفرعية من النوع *EBV2*. على حد علمنا هذه هي المرة الأولى التي يتم فيها تسجيل مثل هذه البيانات في العراق. كانت اهم الاستنتاجات ان كثير من حالات الاصابات بالأورام اللمفاوية اللاهودجكين مرتبطة مع فايروس ابسن بار. هناك اختلاف في توزيع أنواع الفايروس وفقاً لأنواع سرطان الغدد اللمفاوية.

## INTRODUCTION

Epstein–Barr virus (EBV) belongs to the group of gamma-herpes viruses and was the first recognized human oncovirus [1]. It infects at least 90% of the population worldwide [2]. EBV associated with several diseases whose incidence varies dramatically in different parts of the world [3]. EBV is associated with different malignancies in different geographic regions remains puzzling and may be related to EBV genotypic variability through specific disease and geographic associations[4]. For instance: gastric and nasopharyngeal carcinoma in the east Asia (china, democratic people's republic of Korea and Taiwan ) [5], Burkitt's lymphoma is a common cancer of children in equatorial Africa and Papua new guinea [6] and infectious mononucleosis (IM) adolescents/young adults from western societies [7]. EBV-associated lymphomas include Non-Hodgkin lymphoma( NHL) and classic Hodgkin Lymphoma (cHL), lymphomas arising in aids patients, immunocompromised individuals, peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, extranodal nasal-type natural killer/T-cell lymphoma, and other rare histotypes [8]. There are two type of EBV, EBV type 1 (EBV1) and EBV type 2 (EBV2). EBV2 varies genotypically from EBV1 in key latency genes [eg, those encoding EBV nuclear antigen 2 (EBNA2), EBNA3a, and EBNA3c][9].

The NHLs are a heterogeneous group of lympho-proliferative malignancies, consists of many subtypes, each with distinct epidemiology, etiology, morphologic, immunophenotypic, and clinical features [10]. NHL is the 8th most commonly diagnosed cancer in men and the 11th in women in the world [11]. The NHL make up around 90% of all malignant Lymphomas [12]. NHL consists of over 60 subtypes, ranging from slow-growing to very aggressive. The three largest subtypes are Diffuse Large B-cell Lymphoma (DLBCL), Follicular lymphoma (FL), and Chronic Lymphocytic Lymphoma / Small Lymphocytic lymphoma (CLL/SLL) [13]. DLBCL is the most common subtype of NHL, constituting 25–30% of adult NHL , FL accounts for approximately 15–20% of adult NHL, BL constitutes 1–5% of adult NHL in Western countries [14]. The NHL constitutes the in the developed world it ranks seven. The most common NHL subtypes by far in developed countries (disregarding CLL and plasma cell entities) are DLBC lymphoma about 30% and FL about 20% [12]. In Africa countries DLBC is the commonest lymphoma (38.2-55%), BL shows that the endemic type is mainly confined to equatorial Africa and has a very close association with the EBV, while the sporadic variant shows only a 20% association with EBV and is seen mainly in

Europe and North America [15]. In Iraq ,age specific incidence rate for NHL by gender 2.88% for male and 1.77% for female in all top cancer in 2009 [16] than in 2011 the incidence rate for NHL, 6.8% for male and 4.48% for female in all ten top cancer [17]. In Kerbela city, NHL record 6.09% as the fifth from ten commonest cancers in 2009 [16]. Therefore aim of this study: to detect EBV type1 and type 2 in subtype of NHL among patients from Kerbela province by using polymerase chain reaction.

## **MATERILS AND METHODS**

This was a laboratory-based retrospective cross-sectional study on archival formalin-fixed paraffin- embedded lymphoma tissue stored from April 2010 to March 2018 in Kerbala city. The study was accomplished at the medical research laboratory of medicine collage of Kerbala University. Al-Kafeel super speciality Hospital, Al-Hussein Teaching Hospital and Al-Sajad laboratory are the sites of helping for the collection of samples. All cases diagnosed as lymphoma depending on clinical history, histopathological examination and immunohistochemical finding.

From forty-four patients with Non Hodgkin lymphomas, archival FFPE tissue stored from April 2010 to March 2018 were collected and studied. The histopathology report of these cases included: all age groups which ranged from 4 years to 86 years old at diagnosis, gender (male 22 and female 22), subtype of NHL and different anatomical tissue were obtained (cervical 27 , groin 5 axillary 4, abdominal 2, tonsil 2, and 1 for submandibular, kidney, pharyngeal and intestine ).

Sections of tissue block were obtained by the cut at 35- micron thickness by the microtome in histopathology laboratory in Al-Hussein Teaching Hospital. Those tissue sections were transferred to labeled sterile containers. Sterile blades and workplace were kept each sample. After each section, the microtome and workplace were disinfected with cotton and bleach 10% in distilled water [18] to avoid the contamination of samples. Gloves were used in all steps of working.

Up to 25 mg tissue sections of FFPE put in 1.5 ml microcentrifuge tube. DNA was extracted by using gSYNCTM DNA Extraction kit (Cat.No.GS100 Geneaid Biotech Ltd. Korea) Purified DNA extraction stored at deep freeze -20 °C.

For the purpose of ensuring the purity of the DNA and the absence of any inhibitor for the process of amplification by using PCR, the human  $\beta$ -actin gene (housekeeping gene) was used as internal control ( Table 1). For accomplished amplify the gene fragment, add 1 $\mu$ l DNA primer (conc.10 Picomole) for each (Forward primer: 5'-GCCATGTACGTTGCTATCC-3' and Reverse primer: 5'-CCGCGCTCGGTGAGGATC-3') primers were obtained From(Bioneer, Korea), 2 $\mu$ l genomic DNA as template and 16  $\mu$ l free nuclease water with 5  $\mu$ l maxime PCR PreMix. The final volume was 25 $\mu$ l. The PCR mixture was done by Thermal Cycler started with initial denaturation at 95 °C for 2 minute, followed by 35cycles including: denaturation at 94 °C for 30 second, annealing at 55 °C for 1 minute and extension at 72 °C for 1 minute flowed elongation at 72 °C for 7 min yield than hold 4°C for indefinite time. Final product was 200 bp. From amplified product, 5 $\mu$ l carry in agarose gel [1.5 gm agarose per 100 ml Tris/ Borate/ Ethylene Diamine Tetra Acetic acid (TBE buffer)] with 1 $\mu$ l ethidium bromide (10 mg/ml) on TBE buffer] by Horizontal Electrophoresis at 70 volts for 60 min. A100 bp ladder suitable for use as molecular weight standards for electrophoresis. Gel visualized by micro DOC Gel Documentation system and documenting the results in photography picture.

Used specific primer to detection EBV and determine the types by PCR technique. Specific prime for EBNA3C gene was used for this purpose. The sequence of this primer is 5'-AGAAGGGGAGCGTGTGTTGT-3'for Forward and 5'-GGCTCGTTTTTACGTCGGC-3'for Reverse. Final product yield 153bp for EBV type 1 and 246bp for EBV type 2. The PCR amplification accomplished by 1.5  $\mu$ l each primer (conc.10pM), 6 $\mu$ l genomic DNA as a template and 11 $\mu$ l nuclease-free water with 5 $\mu$ l maxime PCR premix kit. Final volume 25 $\mu$ l. PCR condition started with initially denaturation at 95°C for 2 minutes followed by 35cycle include denaturation at 94 °C for 30 seconds, annealing at 55 °C for 45 seconds and extension at 72 °C for 1 minute. Finally, elongation at 72°C for 7 minutes produces than hold 4°C for an indefinite time. From final amplified product carried 5 $\mu$ l in agarose gel [1.5 gm agarose per 100 ml TBE buffer with 1 $\mu$ l ethidium bromide

(10 mg /ml) on TBE buffer] by Horizontal Electrophoresis at 70 volts for 60 minutes. A100 bp ladder was suitable for use as molecular weight standards for electrophoresis. Gel visualized by micro DOC Gel Documentation system and documenting the results in photography picture.

Data were analyzed with Statistical Package for the Social Science (SPSS) Software Version 22 for Windows. T test and chi-square were used to determine statistically association between EBV state with age, age group and subtype of NHL.

This study is restricted by working at the laboratory and there is not close contact with patients. Ethic’s approval was obtained from Kerbala Health Directorate number 3522 on 11 December 2017. All wasted materials and pieces of equipment were collected, packaged and delivered to the Al-Hussein Teaching Hospital for a good and safe disposable by burning.

**RESULTS**

All the NHL blocks which were 44 samples with mean age 45.9±22.8 stored from April 2010 to March 2018 that documented by histopathology report as NHL included in this study (Table 2). NHL was affected 22 out of 44(50%) male with mean age 36.3± 24.6 and 22(50%) out of 44 with mean age 55.4±16.5 female (Figure1). NHL most affected age group were those aged group over 60 years (Figure2). Of all cases, DLBC was reported 28(64%) with mean age 55.7±17.8, T-cell rich Diffuse large B-cell 9(21%) with mean age 34.0±19.7, BL 3(7%) with mean age 5.6±1.5 and 4(8%) for other subtype (Table 3).


Beta-actin (a housekeeping gene) was used as internal PCR control to ensure the efficiency of the DNA extraction procedure. Specific primers were used to amplify 200bp fragments. Figure 3 showed 200 bp amplified products were successfully amplified from all DNA extracts. Both type EBV1 and EBV2 were detectable by amplified fragment 153bp for EBV1 and 246bp for EBV2 by targeted EBNA3C gene (Figure 4). Of all 44 NHL analyzed in this study, DNA of EBV was detected in 21 (47.7%) with mean age 45.4±22.9 while 23(52.3%) with mean age 46.5±23.3 were EBV negative (Figure5) and (Table3). Of all EBV detection in NHL, 12(57.1%) were DLBC, T-cell rich Diffuse large B-cell 5(23.8%), BL2 (9.5%) and 1(4.8%) for each Small B-lymphocytic (SBL) and high grade B cell (CD20 -ve , CD3 -ve) . In NHL positive result for EBV, EBV1 was detected in 13 cases and 8 for EBV2 (Figure 7).

**Table 1: Sequence of primer that used in this study and there NCBI reference**


<b>Gene</b>	<b>Primer sequence</b>		<b>Product size (bp)</b>	<b>NCBI Reference</b>
<b>β-actin</b>	<b>F</b>	GCCATGTACGTTGCTATCC	200	<b>AK223055.1</b>
	<b>R</b>	CCGCGCTCGGTGAGGATC		
<b>EBNA3C</b>	<b>F</b>	AGAAGGGGAGCGTGTGTTGT	153 For EBV1	<b>NC_007605.1</b>
	<b>R</b>	GGCTCGTTTTTGACGTCGGC	246 for EBV2	<b>NC_009334.1</b>

**Table2: characteristic of all NHL cases.**

Type of lymphoma	N	Mean age $\pm$ SD	Gender	N	Mean age $\pm$ SD
NHL	44	45.89 $\pm$ 22.868	Male	22	36.32 $\pm$ 24.610
			female	22	55.45 $\pm$ 16.532



**Figure1: distribution of gender in NHL in this study**



**Figure2: Distribution of age range in NHL**

**Table2: characteristic of subtype of NHL in this study**

<b>Subtype</b>	<b>N (percent)</b>	<b>Mean Age <math>\pm</math> SD</b>
diffuse large B-cell (DLBC)	28 (64%)	55.8 $\pm$ 17.8
T-cell rich Diffuse large B-cell	9 (21%)	34.0 $\pm$ 19.7
High grade B-cell, Burkitt-like(BL)	3 (7%)	5.6 $\pm$ 1.5
Small B-lymphocytic (SBL)	2 (4%)	45.0 $\pm$ 21.2
high grade B cell (CD20 -ve , CD3 -ve)	1 (2%)	9.0
Peripheral T-cell	1 (2%)	35.0
<b>Total</b>	<b>44 (100%)</b>	<b>45.9<math>\pm</math>22.8</b>



Figure 3:  $\square$ -actin (control) in selected sample. Lane 1, 100bp DNA ladder, lane2, 3, 4, 5, 6 positive results for EBV1. Lane 7, 8,9,10 positive results for EBV2







Figure 3.8: EBV detection and subtyping. Lane 1, 100bp DNA ladder .Lane2 negative control , lane 3 positive control for EBV1, Lane 4 positive control for EBV2, Lane 5,7,8,9,10 positive result for EBV1. Lane 6 positive results for EBV2.

**Figure 5: EBV DNA detection in all NHL**





**Figure 6: EBV DNA detection in all NHL subtype**



**Figure7: distribution of EBV type1 type 2 in NHL**



**Table 3A: Distribution of mean age of EBV in NHL**

<b>NHL</b>	<b>EBV Result</b>	<b>№.of cases</b>	<b>Mean Age</b>	<b>Std. Deviation</b>	<b>T.Test Result Sig.</b>
	<b>EBV +ve</b>	21	45.24	22.897	0.860*
	<b>EBV -ve</b>	23	46.48	23.339	

\*Non-statistically significant ( $p = > 0.05$ )

**Table 3B: comparison of age according EBV types**

	<b>EBV TEST</b>	<b>EBV CASES</b>	<b>№.of cases</b>	<b>MEAN Age</b>	<b>Std. Deviation±</b>	<b>T.TEST RESULT sig.</b>
<b>NHL</b>	<b>EBV1 vs. EBV2</b>	<b>EBV 1</b>	13	48.62	±23.013	0.403*
		<b>EBV 2</b>	8	39.75	±23.119	
	<b>EBV1 vs. EBV -ve</b>	<b>EBV 1</b>	13	48.62	±23.013	0.792*
		<b>EBV -ve</b>	23	46.48	±23.339	
	<b>EBV2 vs. EBV -ve</b>	<b>EBV2</b>	8	39.75	±23.119	0.487*
		<b>EBV -ve</b>	23	46.48	±23.339	

\*Non-statistically significant ( $p = > 0.05$ )

**DISCUSSION**

Epidemiologic, serologic and molecular studies have all suggested that EBV is involved in the development of a significant proportion of lymphoma [19]. The identification of strain variants is an effective approach to investigating virus transmission and persistence [20]. Diagnostic information regarding the prognosis and treatment of EBV-associated malignancies was more dependent upon the accurate morphological classification of these tumors than on whether EBV was identified [21].

The peak of the incident of NHL in this study was at the age range of over 60. This was consistent with studies and statistics in Iraq [16], Iran [22], Saudi Arabia [23] and in Central and South America [24] but was not consistent with some studies in Turkey [25] and Jordan [26]. Males are at higher risk of developing NHL and the incidence rises steeply with age [11]. There are 40 different subtypes of NHL which can occur at all ages; however the average age of diagnosis is in over 60 year and the incidence of this disease generally increased with age [27]. The cause of NHL remains unclear, but it is related to immune deficiency, ionization radiation, and viral infection [28].

The DLBC was approximately two-thirds of the specimens which diagnosed as NHL followed T-cell rich Diffuse large B-cell then BL without any statistically significant association between NHL

subtype to age range and NHL subtype to gender (chi-square analyses failed because 95.2%, 83.3% of data have expected count less than 5 respectively ). This result of DLBC consist with Iraqi study [29] Iranian study [30], Turkey [31], Algeria [32], Guatemala [33] central and south America [34] Far East [35] and Australia [36] . The DLBCL is the most frequent type of B-cell lymphoma, accounting for 30%-40% of NHL. The biological properties, genetic mutations, immune phenotypes, and cell morphology of DLBCL are varied, and therefore, DLBCL is considered a heterogeneous group [37].

. From the reviewing, the percentage of cases that EBV infection with NHL, the study find agrees with Iraqi studies which have reported of the EBV in NHL( 40%) out of 15 cases [38] and 14( 43%) of all 32 cases [39]. The results in this study are not compatible with several studies of Iraq's neighbors, for instant: Iran 9(26.5%) out of 34 cases [40] , Jordan 8( 32%) out of 25 cases [41] and Turkey study 14(27.4%) out of 51 cases [42]. Compare this study with Uganda study, here was a vast difference in the result , 87(79.8%) out of 109 cases [43]. This large difference in results may be due to widespread of the EBV in Africa to earlier age of EBV infection and lower socioeconomic status have been related to increased EBV-associated BL in developing countries [44]. The NHL and EBV relation is weaker than the HL relation. However, the EBV plays an active role in the pathogenesis even in some types of NHL. The positive rates of EBV, indicate that EBV has a disease-predisposing role in a significant proportion of lymphoma patients; but it is noteworthy that socioeconomic conditions, genetic characteristics and immunosuppressive factors are important in the development of the disease as a whole [42].

Taking into consideration the size of the sample, subtype of BL more affected with EBV compare with another subtypes of NHL in this study. Depended on marked variation across different geographical regions with respect to age-specific incidence and primary tumor site [45], There are two forms of BL: endemic and sporadic [46], endemic BL diagnosed mostly in children, more frequently in boys than in girls observed south of the Sahara desert and in Papua New Guinea [47] while sporadic form mostly in children and adolescents observed outside Equatorial Africa and Papua New Guinea [48] all cases in this study of BL were endemic (age 3-10 years) and this result conduct with Western Iraqi study [49] but contrast with another [50]. This finding compatible with Iranian study[51] and Northeast Brazil [52]

From the reflection and reviewing the results in this study found that the type of EBV1 more affected than EBV2 in patients with NHL in Kerbala city without any statistically significant association between EBV types to the age range (chi-square analyses failed because 100% of data have expected count less than 5), EBV types to gender (chi-square analyses failed because 100% of data have expected count less than 5) and EBV types to NHL subtype (chi-square analyses failed because 100% of data have expected count less than 5). To the best of our knowledge, no study from the kerbala city and Iraq investigated the link between the type of EBV and NHL subtype. The tow types of EBV distinguished by the differences in EBNA-2gene, since the divergence in EBNA-2 reveals only 54% homology between the two types [53]. Interestingly, it was found that the EBV types noticeably differ in their transformation abilities. For instance, the EBV type 1 transforms the B lymphocytes more willingly than type 2 *in vitro*, and when a recombinant type 2 virus acquired the Type 1 EBNA-2A gene, it gained the transforming ability of type 1 virus [54]. One study suggest that EBV2 is an important human pathogen that present in a wider geographic distribution of HIV associated NHL than originally thought [55].

**REFERANCE**

- [1] Vranic S, Cyprian FS, Akhtar S, Moustafa A. The role of Epstein-Barr virus (EBV) in cervical cancer: A brief update. *Frontiers in oncology* 2018;8:113.
- [2] Dunmire SK, Verghese PS, Balfour HH. Primary Epstein-Barr virus infection. *Journal of Clinical Virology* 2018;102:84.
- [3] Ahmed HM, Khan A, Lam W, Abohamad S, Phatak P. A rare case of three distinct Epstein-Barr virus associated lymphoproliferative disorders over sixteen years of human immunodeficiency virus infection. *Hematology reports* 2017;9.
- [4] Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. *Virus Research* 2009;143:209.
- [5] Khan G, Hashim MJ. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. *Infectious agents and cancer* 2014;9:38.
- [6] Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. *Critical reviews in oncology/hematology* 2000;34:27.
- [7] Macsween KF, Crawford DH. Epstein-Barr virus—recent advances. *The Lancet infectious diseases* 2003;3:131.
- [8] Gala R, Gandhi JS, Gupta G, Grover SK, Sharma A, Pasricha S, et al. Study of association of Epstein-Barr virus in lymphomas by Epstein-Barr virus-encoded RNA in situ hybridization: An Indian perspective from a tertiary care cancer institute. *Indian Journal of Pathology and Microbiology* 2017;60:341.
- [9] Coleman CB, Daud II, Ogolla SO, Ritchie JA, Smith NA, Sumba PO, et al. Epstein-Barr Virus Type 2 Infects T Cells in Healthy Kenyan Children. *The Journal of infectious diseases* 2017;216:670.
- [10] Sharma M, Mannan R, Madhukar M, Navani S, Manjari M, Bhasin TS, et al. Immunohistochemical (IHC) Analysis of Non-Hodgkin's Lymphoma (NHL) Spectrum According to WHO/REAL Classification: A Single Centre Experience from Punjab, India. *Journal of Clinical and Diagnostic Research : JCDR* 2014;8:46.
- [11] Boffetta P. I. Epidemiology of adult non-Hodgkin lymphoma. *Annals of oncology* 2011;22:iv27.
- [12] Ekström-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma – a review. *Acta Oncologica* 2006;45:258.
- [13] Li Y, Wang Y, Wang Z, Yi D, Ma S. Racial differences in three major NHL subtypes: Descriptive epidemiology. *Cancer Epidemiology* 2015;39:8.
- [14] Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. *Expert Review of Anticancer Therapy* 2015;15:531.
- [15] Stefan DC, Lutchman R. Burkitt lymphoma: epidemiological features and survival in a South African centre. *Infectious Agents and Cancer* 2014;9:19.
- [16] Iraqi Cancer Registry 2009. Iraqi cancer registry 2009. 1 ed. Iraq Baghdad Iraqi Cancer Registry; 2012, p. 5.
- [17] Iraqi Cancer Registry 2011. Iraqi Cancer Registry 2011. In: Board IC, editor. 12 ed. Iraq - Baghdad Iraqi ministry of health 2014, p. 5.
- [18] Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML. Epstein-Barr Virus Quantitation by Real-Time PCR Targeting Multiple Gene Segments: A Novel Approach to Screen for the Virus in Paraffin-Embedded Tissue and Plasma. *The Journal of Molecular Diagnostics* 2004;6:378.

- [19] Prabhu SR, Wilson DF. Evidence of Epstein–Barr virus association with head and neck cancers: a review. *J Can Dent Assoc* 2016;82:1488.
- [20] Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein-Barr virus strains in asymptomatic carriers. *Journal of virology* 2003;77:1840.
- [21] Michelow P, Wright C, Pantanowitz L. A review of the cytomorphology of Epstein-Barr virus-associated malignancies. *Acta cytologica* 2012;56:1.
- [22] Najafi S, Payandeh M, Sadeghi M. Clinicopathology figures and survival of non-hodgkin's lymphoma in Iran. *Iranian Journal of Cancer Prevention* 2017;10.
- [23] Alghamdi IG, Hussain II, Alghamdi MS, Dohal AA, Alghamdi MM, El-Sheemy MA. Incidence rate of non-hodgkin's lymphomas among males in Saudi Arabia: an observational descriptive epidemiological analysis of data from the Saudi Cancer Registry, 2001–2008. *International journal of general medicine* 2014;7:311.
- [24] Diumenjo MC, Abriata G, Forman D, Sierra MS. The burden of non-Hodgkin lymphoma in Central and South America. *Cancer Epidemiology* 2016;44:S168.
- [25] Isikdogan A, Ayyildiz O, Buyukcelik A, Arslan A, Tiftik N, Buyukbayram H, et al. Non-Hodgkin's lymphoma in southeast Turkey: clinicopathologic features of 490 cases. *Annals of hematology* 2004;83:265.
- [26] Almasri NM, Habashneh MA, Khalidi HS. Non-Hodgkin lymphoma in Jordan. Types and patterns of 111 cases classified according to the WHO classification of hematological malignancies. *Saudi medical journal* 2004;25:609.
- [27] Ali SHM, Hammodi SR, Amir AHA. In Situ Hybridization for Detection of Latent Epstein-Barr Virus Early Repeats (EBERS) and Mutant-P53-Tumor Suppressor Gene in Patients with Non-Hodgkins Lymphoma. *Journal of the Faculty of Medicine* 2013;55:135.
- [28] Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. *The oncologist* 2008;13:577.
- [29] Alwan AF, Al-Rahal NK. Incidence of Epstein Barr Virus infection in newly diagnosed non-Hodgkin lymphoma in the national center of hematology-single center study. *Iraqi Journal of Cancer and Medical Genetics* 2014;7:21.
- [30] Shamloo N, Ghannadan A, Jafari M, Ahmadi S, Mortazavi H, Baharvand M. Head and Neck Lymphoma in an Iranian Population. *Iranian journal of otorhinolaryngology* 2017;29:261.
- [31] SAĞLAM A, ESİN E, HAYRAN M, BOYRAZ B, ÜNER A. Distribution of lymphomas in Turkey: data of 4239 cases from a single institution using the WHO classification. *Turkish journal of medical sciences* 2018;48:1013.
- [32] Boudjerra N, Perry AM, Audouin J, Diebold J, Nathwani BN, MacLennan KA, et al. Classification of non-Hodgkin lymphoma in Algeria according to the World Health Organization classification. *Leukemia & lymphoma* 2015;56:965.
- [33] Perry AM, Molina-Kirsch H, Nathwani BN, Diebold J, MacLennan KA, Müller-Hermelink HK, et al. Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system. *Leukemia & lymphoma* 2011;52:1681.
- [34] Laurini JA, Perry AM, Boilesen E, Diebold J, MacLennan KA, Müller-Hermelink HK, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. *Blood* 2012:1000.
- [35] Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project. *Annals of hematology* 2016;95:245.
- [36] van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006. *International journal of cancer* 2014;135:2146.
- [37] Shimono J, Miyoshi H, Kiyasu J, Kamimura T, Eto T, Miyagishima T, et al. Clinicopathological analysis of polyploid diffuse large B-cell lymphoma. *PloS one* 2018;13:e0194525.

- [38] Al-Hasnawy HH, Al-Hassnawi AT, Al-Ameri AM. Detection of Epstein Barr Virus Imp-1 gene associated with lymphoma. *International Journal of PharmTech Research* 2016;9:214.
- [39] Al-Qays SA. Detection of Epstein Barr Virus Imp-1 Gene in Non Hodgkin Lymphoma Iraqi Patients. *Medical Journal of Babylon* 2014;11:518.
- [40] Abadi RZM, Sistani NS, Mohtasham N, Hesari KK, Vaezi T, Pazouki M, et al. The prevalence of Epstein-Barr virus infection in head and neck non-Hodgkin's lymphomas in Khorasan, northeast of Iran. *J Pak Med Assoc* 2013;63:882.
- [41] Irshaid F, Jaran A, Dilmi F, Tarawneh K, Hadeth R, Al-Khatib A. Prevalence of Epstein Barr virus latent membrane protein-1 in Jordanian Patients with Hodgkin's lymphoma and non-Hodgkin's lymphoma. *J Biol Sci* 2010;10:507.
- [42] Bağır EK, Açıklan A, Ergin M, Sezgin G, Küpeli S, Seydaoğlu G. Histopathologic subtypes of pediatric lymphomas and relation to Epstein-Barr virus: an immunohistochemical and in-situ hybridization study. 2018.
- [43] Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SA. EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. *Infectious agents and cancer* 2010;5:12.
- [44] Klumb CE, Hassan R, De Oliveira DE, De Resende LMM, Carriço MK, De Almeida Dobbin J, et al. Geographic variation in Epstein- Barr virus-associated Burkitt's lymphoma in children from Brazil. *International journal of cancer* 2004;108:66.
- [45] Hassan R, Klumb CE, Felisbino FE, Guiretti DM, White LR, Stefanoff CG, et al. Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt's lymphoma in Southeastern Brazil: epidemiological insights from an intermediate risk region. *Haematologica* 2008;93:780.
- [46] Grywalska E, Rolinski J. Epstein-Barr Virus-Associated Lymphomas. *Seminars in Oncology* 2015;42:291.
- [47] Lenze D, Leoncini L, Hummel M, Volinia S, Liu C, Amato T, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. *Leukemia* 2011;25:1869.
- [48] Kelly GL, Stylianou J, Rasaiyaah J, Wei W, Thomas W, Croom-Carter D, et al. Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. *Journal of virology* 2013;87:2882.
- [49] Al-Fahdawi KA, Al-Zobae MA, Al-Esawi AO. Association Between Epstein-Barr Virus and Burkitt's lymphoma in Western Iraq.(A molecular case-control study. *Al-Anbar Medical Journal* 2016;13:114.
- [50] Al-Attar A, Al-Mondhiry H, Al-Bahrani Z, Al-Saleem T. Burkitt's lymphoma in Iraq. Clinical and pathological study of forty-seven patients. *International Journal of Cancer* 1979;23:14.
- [51] Shah KM, Young LS. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. *Clinical Microbiology and Infection* 2009;15:982.
- [52] Araujo I, Foss H, Bittencourt A, Hummel M, Demel G, Mendonca N, et al. Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil. *Blood* 1996;87:5279.
- [53] Münz C. Epstein Barr virus volume 1: Springer International Editor; 2015.
- [54] Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. *Journal of virology* 1987;61:1310.
- [55] Boyle M, Sewell W, Sculley T, Apolloni A, Turner J, Swanson C, et al. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. *Blood* 1991;78:3004.